AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00335452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: oral administration
Study NCT01733290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
Study NCT01733290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline instillation
Description: Normal saline instillation
Study NCT02526420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
Study NCT01091857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIDE
Study NCT01091857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STRIDE
Study NCT01037517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
Study NCT01037517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation: Nonintervention
Description: Nonintervention group, no drug will be given, observation only
Study NCT01063621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6500
Description: Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
Study NCT04138472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
Study NCT04138472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
Study NCT00335452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: oral administration
Study NCT00335452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicyclic acid (ASA)
Description: oral administration
Study NCT00335452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicyclic acid (ASA)
Description: oral administration
Study NCT04138472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
Study NCT02811146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Pressure Airway
Description: Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
Study NCT02811146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rehabilitation
Description: Heart rehabilitation, for 12 weeks, 3 times a week
Study NCT02923804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 3x 1g capsules taken daily for 6 months
Study NCT02923804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: 3x 1g capsules taken daily for 6 months
Study NCT01355588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: 30 mg Ketorolac Tromethamine intranasal (IN)
Study NCT01355588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)
Description: 30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
Study NCT01355588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine with 5% Lidocaine HCl
Description: 30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
Study NCT01355588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl
Description: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
Study NCT00746122 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open repair
Description: Standard treatment of emergency open surgery
Study NCT00746122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVAR
Description: Emergency endovascular aneurysm repair
Study NCT00002611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin
Study NCT00002611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00002611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00002611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
Study NCT02984306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry powder
Study NCT02984306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT05304299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps Cicadae Mycelia
Description: Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
Study NCT03757455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol preoperative actions
Description: First appointment:~- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting
Study NCT03757455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol intraoperative actions
Description: Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery
Study NCT00002611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00002611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00002611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00002611 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT04285008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pure-Vu System
Description: The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
Study NCT01280838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hombre Seguro
Description: A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
Study NCT01280838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic attention-control condition
Description: The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
Study NCT01843192 — intervention group
Intervention type: DEVICE
Intervention: Endocutter
Study NCT00522301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT00522301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00522301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00522301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00522301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT03488368 — intervention group
Intervention type: OTHER
Intervention: observation
Description: Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
Study NCT04562961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schizophrenia caregivers qualitative interview
Description: The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center.
Study NCT02742298 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Muscle ultrasound
Description: Ultrasound images of limb muscles will be collected.
Study NCT02742298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrical Impedance Myography
Description: A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
Study NCT02281448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093
Study NCT02281448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Contraceptives, Oral, Combined
Study NCT02430402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation in warm climate
Study NCT03395405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One 500 mg tablet twice daily with food for 56 consecutive doses
Study NCT03395405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice daily with food for 56 consecutive doses
Study NCT02580708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Study NCT02580708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study NCT00778128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4126
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
Study NCT00778128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
Study NCT03944525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: Oxygen-therapy via HFNC
Study NCT03944525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Non-invasive CPAP ventilation
Study NCT03813238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: Dosage ranging from 6 mg to 48 mg.
Study NCT03813238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage ranging from 6 mg to 48 mg.
Study NCT05190250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pipelle biopsy
Description: Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
Study NCT02080871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting of the Common and/or External Iliac Arteries
Description: Balloon expandable stenting of iliac occlusive disease.
Study NCT02507518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan imaging
Description: a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
Study NCT01941732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study NCT02745665 — intervention group
Intervention type: OTHER
Intervention: flow mediated dilation (endothelial function)
Study NCT02745665 — intervention group
Intervention type: OTHER
Intervention: ABPI
Study NCT02745665 — intervention group
Intervention type: OTHER
Intervention: Pulse wave velocity and augmentation index
Study NCT02745665 — intervention group
Intervention type: OTHER
Intervention: blood pressure
Study NCT02745665 — intervention group
Intervention type: OTHER
Intervention: ramp test
Study NCT02710279 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trier Social Stress Test (TSST)
Description: For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days.
Study NCT02710279 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone
Study NCT01939873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KRISTELLER
Study NCT01271348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Etoricoxib film tablet, 90 mg, q.d.
Study NCT01271348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet, q.d.
Study NCT01174420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of ologen Collagen Matrix in trabeculectomy
Description: After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
Study NCT01174420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Mitomycin-C in trabeculectomy
Description: After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
Study NCT03820856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture plus fire needle therapy
Description: The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
Study NCT03820856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
Study NCT02771444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomo Assessment
Description: A four-view tomosynthesis examination
Study NCT03338894 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga
Description: 1 Hour yoga class
Study NCT04900129 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%
Description: inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
Study NCT02340741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional prophylaxis of aeroembolism
Description: 167 patients will be enrolled. Will perform standard way of aeroembolism prevention
Study NCT02340741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional prophylaxis plus CO2 insufflation
Description: 167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
Study NCT02340741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery with opening of heart chambers
Description: Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
Study NCT02982525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No Mussels
Description: Habitual diet only
Study NCT02982525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One mussel portion
Description: 1 x 75g mussel portions provided per week
Study NCT02982525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Two mussel portions
Description: 2 x 75g mussel portions provided per week
Study NCT02982525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Three mussel portions
Description: 3 x 75g mussel portions provided per week
Study NCT03476629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Effects of different physical activity programs
Study NCT03757455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol postoperative actions
Description: Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility
Study NCT03622502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
Study NCT03622502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
Study NCT03622502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
Study NCT03622502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline was infused over 10 min before end of the surgery
Study NCT03112356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Leukoscan® scintigraphy
Description: Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
Study NCT04690413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOWDx COVID-19 Test
Description: The investigational device is the NOWDx COVID-19 Test.
Study NCT01729936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting time Change Intervention
Description: Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
Study NCT02232074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient navigation enhanced with legal support
Study NCT02607800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg tablet administered orally once daily with food